Description
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer
Location: CPMC (San Francisco)
Please contact: Clinicalresearch@sutterhealth.org for information about Merck 7339-007
View study details on ClinicalTrials.govPrincipal Investigator
Co-Investigator(s)
Kevin Kim, MD, Lejla Delic, MD
Recruitment Status
Active, Not Recruiting
Start Date
December 20, 2019
Related Studies
Breast Cancer Chemoprevention in Primary Care at Geisinger
Identify PCPs’ awareness of breast cancer risk assessment and breast cancer chemoprevention
knowledge, and identify perceived barriers and clinic solutions.
Investigators: Xiaowei (Sherry) Yan, PhD, MS, External PI, Principal Investigator
Impact of COVID-19 on Cancer Care Management
Study will enhance understanding of cancer care management due to COVID-19.
Investigators: Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.